Total Payments
$32,886
2024 Payments
$111.36
Companies
79
Transactions
635
Medicare Patients
3,292
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$15,234 (46.3%)
Consulting$9,235 (28.1%)
Other$5,200 (15.8%)
Travel$2,141 (6.5%)
Education$1,075 (3.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,234 | 593 | 46.3% |
| Consulting Fee | $9,235 | 4 | 28.1% |
| Honoraria | $3,850 | 2 | 11.7% |
| Travel and Lodging | $2,141 | 7 | 6.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,350 | 1 | 4.1% |
| Education | $1,075 | 28 | 3.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $4,255 | 11 | $0 (2020) |
| Spectrum Pharmaceuticals Inc. | $3,698 | 7 | $0 (2018) |
| Jazz Pharmaceuticals Inc. | $3,401 | 8 | $0 (2020) |
| Pharmacosmos Therapeutics Inc. | $2,300 | 1 | $0 (2021) |
| Karyopharm Therapeutics Inc. | $1,705 | 5 | $0 (2021) |
| Genentech USA, Inc. | $1,626 | 70 | $0 (2021) |
| Amgen Inc. | $1,391 | 46 | $0 (2023) |
| Immunomedics, Inc. | $1,363 | 2 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $1,340 | 36 | $0 (2021) |
| Celgene Corporation | $1,089 | 19 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $111.36 | 4 | Regeneron Healthcare Solutions, Inc. ($56.63) |
| 2023 | $180.85 | 5 | BeiGene USA, Inc. ($102.92) |
| 2022 | $502.19 | 5 | TerSera Therapeutics LLC ($129.18) |
| 2021 | $4,079 | 72 | Pharmacosmos Therapeutics Inc. ($2,300) |
| 2020 | $6,293 | 117 | Karyopharm Therapeutics Inc. ($1,686) |
| 2019 | $6,973 | 148 | JAZZ PHARMACEUTICALS INC. ($3,344) |
| 2018 | $7,182 | 141 | Spectrum Pharmaceuticals Inc. ($3,698) |
| 2017 | $7,565 | 143 | Bayer HealthCare Pharmaceuticals Inc. ($4,056) |
All Payment Transactions
635 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $56.63 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $28.65 | General |
| 10/02/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $5.40 | General |
| Category: Narcoplepsy | ||||||
| 04/18/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $20.68 | General |
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | ABILIFY (Drug) | Education | In-kind items and services | $22.41 | General |
| Category: Neuroscience | ||||||
| 09/26/2023 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Oncology | ||||||
| 08/08/2023 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: Analgesic | ||||||
| 03/28/2023 | Amgen Inc. | — | Education | In-kind items and services | $15.49 | General |
| 02/28/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $102.92 | General |
| Category: Oncology | ||||||
| 09/14/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $88.14 | General |
| Category: ONC | ||||||
| 08/30/2022 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $116.08 | General |
| 08/25/2022 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $129.18 | General |
| Category: Oncology | ||||||
| 06/28/2022 | EMD Serono, Inc. | — | Education | In-kind items and services | $43.80 | General |
| 02/17/2022 | G1 Therapeutics, Inc. | COSELA (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2021 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: Oncology | ||||||
| 11/18/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 11/16/2021 | G1 Therapeutics, Inc. | COSELA (Drug) | Food and Beverage | Cash or cash equivalent | $66.25 | General |
| Category: ONCOLOGY | ||||||
| 09/22/2021 | Pharmacosmos Therapeutics Inc. | Monoferric (Drug) | Honoraria | Cash or cash equivalent | $2,300.00 | General |
| Category: Hematology | ||||||
| 08/05/2021 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $62.43 | General |
| 07/29/2021 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: Oncology/Endocrinology | ||||||
| 07/28/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: ONCOLOGY | ||||||
| 07/28/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2021 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $21.77 | General |
| 07/22/2021 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $21.15 | General |
| Category: Oncology | ||||||
| 07/22/2021 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 304 | 509 | $92,721 | $44,303 |
| 2022 | 6 | 460 | 785 | $145,605 | $77,592 |
| 2021 | 24 | 1,190 | 47,692 | $951,358 | $475,012 |
| 2020 | 25 | 1,338 | 39,505 | $997,310 | $487,679 |
Total Patients
3,292
Total Services
88,491
Medicare Billing
$1.1M
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 78 | 190 | $33,415 | $20,129 | 60.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 177 | 269 | $36,185 | $17,471 | 48.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 26 | $15,645 | $3,473 | 22.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 24 | 24 | $7,476 | $3,230 | 43.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 148 | 360 | $61,289 | $40,295 | 65.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 201 | 313 | $40,573 | $22,474 | 55.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 47 | 47 | $12,108 | $6,619 | 54.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 36 | 37 | $21,458 | $5,711 | 26.6% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 17 | 17 | $5,215 | $1,334 | 25.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 11 | $4,962 | $1,158 | 23.3% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2021 | 13 | 5,800 | $429,200 | $237,370 | 55.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 18 | 3,720 | $119,040 | $60,229 | 50.6% |
| Q5111 | Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg | Office | 2021 | 12 | 228 | $121,980 | $47,141 | 38.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 89 | 179 | $34,010 | $24,777 | 72.9% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2021 | 49 | 31,110 | $46,665 | $23,368 | 50.1% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 75 | 167 | $41,750 | $17,426 | 41.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 103 | 180 | $27,000 | $16,276 | 60.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 57 | 60 | $20,989 | $9,514 | 45.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 38 | 38 | $10,450 | $6,505 | 62.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 29 | 48 | $8,097 | $5,616 | 69.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 57 | 77 | $10,010 | $3,687 | 36.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 41 | 43 | $5,244 | $3,386 | 64.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 206 | 425 | $6,375 | $3,287 | 51.6% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 48 | 252 | $7,560 | $2,981 | 39.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 31 | $7,772 | $2,535 | 32.6% |
About Dr. David Eilender, MD
Dr. David Eilender, MD is a Hematology & Oncology healthcare provider based in Soldotna, Alaska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700823705.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Eilender, MD has received a total of $32,886 in payments from pharmaceutical and medical device companies, with $111.36 received in 2024. These payments were reported across 635 transactions from 79 companies. The most common payment nature is "Food and Beverage" ($15,234).
As a Medicare-enrolled provider, Eilender has provided services to 3,292 Medicare beneficiaries, totaling 88,491 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Soldotna, AK
- Active Since 05/31/2006
- Last Updated 01/08/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1700823705
Products in Payments
- Non-Covered $4,000
- VYXEOS (Drug) $3,360
- Folotyn (Drug) $3,135
- Monoferric (Drug) $2,300
- XPOVIO (Drug) $1,705
- TRODELVY (Drug) $1,350
- LYNPARZA (Drug) $902.39
- KEYTRUDA (Biological) $562.71
- TECENTRIQ (Biological) $519.27
- DARZALEX (Biological) $495.76
- OPDIVO (Biological) $465.50
- Cabometyx (Drug) $391.23
- IMBRUVICA (Drug) $347.51
- Vectibix (Biological) $347.11
- ADCETRIS (Biological) $344.58
- Onivyde (Drug) $317.18
- ZEJULA (Drug) $316.63
- Zydelig (Drug) $306.03
- BRUKINSA (Drug) $293.38
- Lenvima (Drug) $292.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.